Ventricular Repolarization and Calcium Transient Show Resonant Behavior under Oscillatory Pacing Rate

Biomolecules. 2022 Jun 23;12(7):873. doi: 10.3390/biom12070873.

Abstract

Cardiac EC coupling is triggered by rhythmic depolarizing current fronts originating from the sino-atrial node, and the way variability in rhythm is associated with variability in action potential duration (APD) and, in turn, in the variability of calcium transient amplitude (CTA) and contraction is a key determinant of beating stability. Sinusoidal-varying pacing rate is adopted here in order to establish whether APD and CTA oscillations, elicited in a human ventricular AP model (OR) under oscillatory pacing, are consistent with the dynamics of two coupled harmonic oscillators, e.g., a two-degree-of-freedom system of mass and springs (MS model). I show evidence that this is the case, and that the MS model, preliminarily fitted to OR behavior, retains key features of the physiological system, such as the dependence of APD and CTA oscillation amplitudes from average value and from beat-to-beat changes in pacing rate, and the phase relationship between them. The bi-directionality of coupling between APD and CTA makes it difficult to discriminate which one leads EC coupling dynamics under variable pacing. The MS model suggests that the calcium cycling, with its greater inertia chiefly determined by the SR calcium release, is the leading mechanism. I propose the present approach to also be relevant at the whole organ level, where the need of compact representations of electromechanical interaction, particularly in clinical practice, remains urgent.

Keywords: cardiac EC coupling; cardiac action potential; cardiac numerical modeling; cardiac repolarization; variability of cardiac pacing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / physiology
  • Calcium Signaling / physiology
  • Calcium* / metabolism
  • Cardiac Pacing, Artificial*
  • Heart Ventricles / metabolism
  • Humans
  • Myocytes, Cardiac / metabolism

Substances

  • Calcium

Grants and funding

This research was supported by funding from Chiesi Pharmaceutical S.p.A., Parma, Italy, to the author.